The biopharmaceutical industry has a rich tradition of innovating with data and analytics to positively impact healthcare. Current emerging trends include the use of modern artificial intelligence, namely machine and deep learning to explore ways in which the lengthy process for drug discovery, development and commercialization can be improved.
In this Frameworx session, Eli Lilly and Company’s Andrea de Souza, Senior Director, Research Data Sciences & Engineering and Jonathan McClain, Advisor, External Innovation & Intelligence will describe the innovation ecosystem and the positive impact that AI is having in healthcare. Specifically, how are healthcare companies exploiting AI to deliver much needed therapies for serious diseases such as cancer and diabetes. The thought provoking presentation will be followed by a thought leadership panel that includes representation from Industry and academia: